Trexquant Investment LP Cuts Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Trexquant Investment LP cut its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 46.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 100,798 shares of the biotechnology company's stock after selling 85,890 shares during the period. Trexquant Investment LP owned 0.08% of Arrowhead Pharmaceuticals worth $1,895,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. BNP Paribas Financial Markets grew its position in shares of Arrowhead Pharmaceuticals by 40.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 55,188 shares of the biotechnology company's stock worth $1,069,000 after buying an additional 15,784 shares during the period. Captrust Financial Advisors bought a new stake in Arrowhead Pharmaceuticals during the third quarter worth about $291,000. HighTower Advisors LLC grew its holdings in Arrowhead Pharmaceuticals by 11.5% in the third quarter. HighTower Advisors LLC now owns 123,477 shares of the biotechnology company's stock worth $2,401,000 after purchasing an additional 12,706 shares during the period. State Street Corp increased its stake in shares of Arrowhead Pharmaceuticals by 8.8% during the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company's stock valued at $123,083,000 after purchasing an additional 516,569 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Arrowhead Pharmaceuticals by 1.5% during the third quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company's stock valued at $1,199,000 after purchasing an additional 886 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Remove Ads

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR traded up $0.08 during trading hours on Monday, hitting $11.87. The stock had a trading volume of 131,829 shares, compared to its average volume of 1,404,465. The firm has a market capitalization of $1.63 billion, a PE ratio of -2.30 and a beta of 0.99. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $30.41. The stock has a fifty day moving average price of $16.07 and a 200 day moving average price of $18.86.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.97). Analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ARWR. Chardan Capital reaffirmed a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. StockNews.com raised Arrowhead Pharmaceuticals to a "sell" rating in a research report on Friday, December 20th. Royal Bank of Canada reiterated an "outperform" rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Finally, B. Riley reiterated a "buy" rating and issued a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $41.44.

Insiders Place Their Bets

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of the stock in a transaction that occurred on Friday, April 11th. The shares were sold at an average price of $11.49, for a total value of $583,692.00. Following the completion of the sale, the chief executive officer now directly owns 3,921,255 shares of the company's stock, valued at approximately $45,055,219.95. This represents a 1.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have sold 276,839 shares of company stock worth $4,054,176. Company insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.